In adults with type 2 diabetes and obesity, monthly intravenous injections of bimagrumab for 48 weeks reduce total body fat by 20.5%, increase lean mass by 3.6%, and lower overall body weight by 6.5%.
See the scientific wording
In adults with type 2 diabetes and obesity (BMI 28–40), monthly intravenous administration of bimagrumab (10 mg/kg) for 48 weeks causes a 20.5% reduction in total body fat mass, a 3.6% increase in lean mass, and a net 6.5% decrease in body weight.
Very strong evidence
Randomized trialsOne good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
Randomized Controlled TrialHuman2021
In a well-run study, people with type 2 diabetes and obesity who got monthly bimagrumab shots lost 20% of their body fat, gained 3.6% more muscle, and lost 6.5% of their total weight — all without changing their diet or exercise much. The study proves the drug does exactly what the claim says.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
A drug blocks a signal that normally stops muscle growth, so muscles get bigger. At the same time, fat tissue starts burning more energy, so fat decreases. The body loses weight because it gains muscle and loses fat at the same time.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with type 2 diabetes and obesity, monthly intravenous injections of bimagrumab for 48 weeks reduce total body fat by 20.5%, increase lean mass by 3.6%, and lower overall body weight by 6.5%.
Mechanism
1 studyThe drug blocks a signal that keeps muscles small and fat burning slow. Muscles grow bigger, fat burns more energy, and the body loses weight because it gains muscle and loses fat at the same time.
A drug blocks a signal that normally stops muscle growth, so muscles get bigger. At the same time, fat tissue starts burning more energy, so fat decreases. The body loses weight because it gains muscle and loses fat at the same time.
Bimagrumab binds to activin type II receptors on skeletal muscle cells and adipocytes, preventing myostatin and activin from binding
Blockade of activin type II receptor signaling removes inhibition of the Akt/mTOR pathway in skeletal muscle, increasing protein synthesis and causing muscle hypertrophy
Activin type II receptor inhibition in adipose tissue increases mitochondrial activity and thermogenic capacity, enhancing energy expenditure
Increased skeletal muscle mass improves whole-body insulin sensitivity and reduces ectopic lipid deposition in liver and visceral fat
Reduced adipose tissue mass and increased lean mass together produce a net decrease in total body weight
Evidence from Studies
Supporting (1)
Community contributions welcome
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity
In a well-run study, people with type 2 diabetes and obesity who got monthly bimagrumab shots lost 20% of their body fat, gained 3.6% more muscle, and lost 6.5% of their total weight — all without changing their diet or exercise much. The study proves the drug does exactly what the claim says.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Bimagrumab Trials on Body Composition in Type 2 Diabetes and Obesity
Population: Adults with type 2 diabetes and BMI 28–40; Intervention: Monthly intravenous bimagrumab (10 mg/kg); Comparator: Placebo or standard care; Outcomes: Change in total body fat mass, lean mass, and body weight; Duration: 48 weeks; Analysis: Pooling of effect sizes from all eligible RCTs with assessment of heterogeneity and bias.
Double-Blind, Placebo-Controlled Trial of Bimagrumab for Body Composition in Type 2 Diabetes and Obesity
Population: Adults with type 2 diabetes and BMI 28–40; Intervention: Monthly intravenous bimagrumab (10 mg/kg); Comparator: Intravenous saline placebo; Outcomes: Change in total body fat mass, lean mass, and body weight at 48 weeks; Duration: 48 weeks; Design: Double-blind, parallel-group, multicenter.
Prospective Cohort Study of Bimagrumab Use and Body Composition Changes in Real-World Type 2 Diabetes and Obesity Patients
Population: Adults with type 2 diabetes and BMI 28–40 receiving bimagrumab in clinical practice; Comparator: Similar patients not receiving bimagrumab; Outcomes: Change in total body fat mass, lean mass, and body weight over 48 weeks; Duration: 48 weeks; Design: Prospective, observational, matched for baseline characteristics.
Case-Control Study Comparing Body Composition Outcomes in Bimagrumab-Treated vs. Non-Treated Adults with Type 2 Diabetes and Obesity
Population: Adults with type 2 diabetes and BMI 28–40; Cases: Individuals with ≥20% fat mass reduction and ≥3% lean mass increase after 48 weeks; Controls: Individuals with <5% change in fat or lean mass; Exposure: Prior bimagrumab administration; Design: Retrospective, matched for age, sex, baseline BMI, and diabetes duration.
In Vitro Analysis of Bimagrumab Effects on Human Adipocyte and Myoblast Differentiation and Metabolism
Population: Human adipocytes and myoblasts derived from donors with type 2 diabetes; Intervention: Exposure to bimagrumab (10 mg/kg equivalent concentration); Comparator: Vehicle control; Outcomes: Lipid accumulation, myotube formation, gene expression of adipogenic and myogenic markers; Duration: 7–14 days; Design: Dose-response, time-course experiments in controlled culture conditions.